HER-2 positivity is a high risk of recurrence of stage I gastric cancer

Background/Aims The treatment of gastric cancer remains unsatisfactory. We aimed to investigate the prognostic value of immunohistochemical staining in gastric cancer. Methods We analyzed 505 (279 early staged, 226 advanced-staged) gastric cancer tissues from patients who underwent radical gastric r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Seonhoo Kim, Yeon-Ji Kim, Woo Chul Chung
Formato:	article
Lenguaje:	EN
Publicado:	The Korean Association of Internal Medicine 2021
Materias:	stomach neoplasms recurrence genes erbb-2 Medicine R
Acceso en línea:	https://doaj.org/article/e125d86b02dc4c33baa8a1e63e2a48ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e125d86b02dc4c33baa8a1e63e2a48ab
record_format	dspace
spelling	oai:doaj.org-article:e125d86b02dc4c33baa8a1e63e2a48ab2021-11-08T00:59:06ZHER-2 positivity is a high risk of recurrence of stage I gastric cancer1226-33032005-664810.3904/kjim.2020.243https://doaj.org/article/e125d86b02dc4c33baa8a1e63e2a48ab2021-11-01T00:00:00Zhttp://www.kjim.org/upload/pdf/kjim-2020-243.pdfhttps://doaj.org/toc/1226-3303https://doaj.org/toc/2005-6648Background/Aims The treatment of gastric cancer remains unsatisfactory. We aimed to investigate the prognostic value of immunohistochemical staining in gastric cancer. Methods We analyzed 505 (279 early staged, 226 advanced-staged) gastric cancer tissues from patients who underwent radical gastric resection between January 2014 and December 2016. Available surgical specimens immunohistochemically stained for p53, epidermal growth factor receptor (EGFR), human EGFR 2 (HER-2), E-cadherin, and Ki-67 were reviewed. We evaluated the association between positivity to various biomarkers and disease recurrence, disease-free survival, lymph node metastasis, and microscopic lymphovascular invasion. Results The median follow-up duration was 32.5 months (range, 7 to 70). Advanced gastric cancer cases showed high Ki-67 expression; other cases showed unremarkable expression. Concerning disease recurrence, lymphatic invasion, and disease-free interval, all biomarkers had no prognostic effects. HER-2-positive stage I gastric cancer tended to occur in old patients and in the upper one-third of the stomach (p = 0.01). HER-2 positivity was significantly correlated with disease recurrence (p = 0.01), lymphatic invasion (p = 0.03), and vascular invasion (p = 0.03) in stage I cases. Conclusions Only HER-2 was associated with the recurrence of stage I gastric cancer. HER-2-positive stage I gastric cancer requires additional therapy despite curative resection.Seonhoo KimYeon-Ji KimWoo Chul ChungThe Korean Association of Internal Medicinearticlestomach neoplasmsrecurrencegenes erbb-2MedicineRENThe Korean Journal of Internal Medicine, Vol 36, Iss 6, Pp 1327-1337 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	stomach neoplasms recurrence genes erbb-2 Medicine R
spellingShingle	stomach neoplasms recurrence genes erbb-2 Medicine R Seonhoo Kim Yeon-Ji Kim Woo Chul Chung HER-2 positivity is a high risk of recurrence of stage I gastric cancer
description	Background/Aims The treatment of gastric cancer remains unsatisfactory. We aimed to investigate the prognostic value of immunohistochemical staining in gastric cancer. Methods We analyzed 505 (279 early staged, 226 advanced-staged) gastric cancer tissues from patients who underwent radical gastric resection between January 2014 and December 2016. Available surgical specimens immunohistochemically stained for p53, epidermal growth factor receptor (EGFR), human EGFR 2 (HER-2), E-cadherin, and Ki-67 were reviewed. We evaluated the association between positivity to various biomarkers and disease recurrence, disease-free survival, lymph node metastasis, and microscopic lymphovascular invasion. Results The median follow-up duration was 32.5 months (range, 7 to 70). Advanced gastric cancer cases showed high Ki-67 expression; other cases showed unremarkable expression. Concerning disease recurrence, lymphatic invasion, and disease-free interval, all biomarkers had no prognostic effects. HER-2-positive stage I gastric cancer tended to occur in old patients and in the upper one-third of the stomach (p = 0.01). HER-2 positivity was significantly correlated with disease recurrence (p = 0.01), lymphatic invasion (p = 0.03), and vascular invasion (p = 0.03) in stage I cases. Conclusions Only HER-2 was associated with the recurrence of stage I gastric cancer. HER-2-positive stage I gastric cancer requires additional therapy despite curative resection.
format	article
author	Seonhoo Kim Yeon-Ji Kim Woo Chul Chung
author_facet	Seonhoo Kim Yeon-Ji Kim Woo Chul Chung
author_sort	Seonhoo Kim
title	HER-2 positivity is a high risk of recurrence of stage I gastric cancer
title_short	HER-2 positivity is a high risk of recurrence of stage I gastric cancer
title_full	HER-2 positivity is a high risk of recurrence of stage I gastric cancer
title_fullStr	HER-2 positivity is a high risk of recurrence of stage I gastric cancer
title_full_unstemmed	HER-2 positivity is a high risk of recurrence of stage I gastric cancer
title_sort	her-2 positivity is a high risk of recurrence of stage i gastric cancer
publisher	The Korean Association of Internal Medicine
publishDate	2021
url	https://doaj.org/article/e125d86b02dc4c33baa8a1e63e2a48ab
work_keys_str_mv	AT seonhookim her2positivityisahighriskofrecurrenceofstageigastriccancer AT yeonjikim her2positivityisahighriskofrecurrenceofstageigastriccancer AT woochulchung her2positivityisahighriskofrecurrenceofstageigastriccancer
_version_	1718443319925669888

HER-2 positivity is a high risk of recurrence of stage I gastric cancer

Ejemplares similares